In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells

Journal of Surgical Research

Volumn 112, Issue 2, 2003, Pages 189-197

  Kass, Rena ^b   Agha, Jamshed ^b   Bellone, Stefania ^a,c   Palmieri, Michela ^a,c   Canè, Stefania ^a,c   Bignotti, Eliana ^a,c   Henry Tillman, Rhonda ^b   Hutchins, Laura ^b   Cannon, Martin J ^b   Klimberg, Suzanne ^b   Santin, Alessandro D ^a,c,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; CTL; Cytokines; Cytotoxicity assays; Dendritic cells; Tumor lysate

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 4; LYMPHOCYTE SURFACE MARKER; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CASE REPORT; CELL LINE; CELL STRAIN K 562; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOBLASTOID CELL; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TUMOR CELL DESTRUCTION; VIRUS CELL TRANSFORMATION;

EID: 0041347751     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-4804(03)00147-1     Document Type: Article

References (45)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistic. CA Cancer J. Clin. 53:2003;5.
2. Riethmuller G., Johnson J.P. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr. Opin. Immunol. 4:1992;647.
3. Brown D.C., Purushotham A.D., Birnie G.D., George W.D. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery. 117:1995;96.
4. Braun S., Kentenich C., Janni W., Hepp F., de Waal J., Willgeroth F., Sommer H., Pantel K. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J. Clin. Oncol. 18:2000;80.
5. Fidler I.J. Modulation of organ environment for treatment of cancer metastases. J. Natl. Cancer Inst. 87:1995;1588.
6. Young J.W., Inaba K. DCs as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:1996;7.
7. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183.
8. Romani N., Gruner S., Brang D., Kampgen E., Lnez A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:1994;83.
9. Sallusto F., Lanzavecchia A. Efficient presentation of soluable antigen by cultured human dendritic cells is maintanined by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by turner necrosis factor alpha. J. Exp. Med. 17:1994;1109.
10. Santin A.D., Hermonat P.L., Ravaggi A., Chiriva-Internati M., Cannon M.J., Hiserodt J.C., Pecorelli S., Parham G.P. Kinetics of expression of surface antigens during the differentiation of human dendritic cells versus macrophages from monocytes in vitro. Immunobiology. 200:1999;187.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245.
12. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Pragnik L., Schmitt E., Knop J., Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:1997;3135.
13. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., Donahoe S.M., Dunbar P.R., Cerundolo V., Nixon D.F., Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:1999;173.
14. Dhodapkar M.V., Krasovsky J., Steinman R.M., Bhardwaj N. Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105:2000;R9.
15. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:2001;233.
16. Peoples G.E., Smith R.C., Linehan D.C., Yoshino I., Goedegebuure P.S., Eberlein T.J. Shared T cell epitopes in epithelial tumors. Cell Immunol. 164:1995;279.
17. Hadden J.W. The immunology and immunotherapy of breast cancer an update . Int. J. Immunopharmacol. 21:2000;79.
18. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M., Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA. 97:2000;2715.
19. Linehan D.C., Goedegebuure P.S., Peoples G.E., Rogers S.O., Eberlein T.J. Tumor specific and HLA-A2 restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155:1995;4486.
20. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52.
21. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328.
22. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E.B., Steinman R.M., Enk A., Kampgen E., Shuler G. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669.
23. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., Chang A.E., Braun T.M., Mule J.J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61:2001;8513.
24. Santin A.D., Bellone S., Gokden M., Cannon M.J., Parham G.P. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. 346:2002;1752.
25. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Pecorelli S., Cannon M.J., Parham G.P. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet. Gynecol. 96:2000;422.
26. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Pecorelli S., Cannon M.J., Parham G.P. Induction of tumor-specific HLA class I restricted CD8+ cytotoxic T lymphocytes by ovarian-tumor antigen pulsed autologous dendritic cells in patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 183:2000;601.
27. Babcock B., Anderson B.W., Papayannopoulos I., Castilleja A., Murray J.L., Stifani S., Kudelka A.P., Wharton J.T., Ioannides C.G. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol. Immunol. 35:1998;1121.
28. Kim D.K., Lee T.V., Castilleja A., Anderson B.W., Peoples G.E., Kudelka A.P., Murray J.L., Sittisomwong T., Wharton J.T., Kim J.W., Ioannides C.G. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res. 19:1999;2907.
29. + cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin. Cancer Res. 7:2001;804s.
30. Maino V.C., Picker L.J. Identification of functional subsets by flow cytometry intracellular detection of cytokine expression . Cytometry. 34:1998;207.
31. Nair S.K., Hull S., Coleman D., Gilboa E., Lyerly H.K., Morse M.A. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer. 82:1999;121.
32. Hammerling G., Maschek V., Sturmhofel K., Momburg F. Regulation and functional role of MHC expression on tumors. Melchers F. Progress in Immunology. 1989;1071-1078 Springer, Berlin.
33. Moretta A., Pantaleo G., Mingari M.C., Melioli G., Moretta L., Cerottini J.C. Assignment of human natural killer (NK)-like cells to the T cell lineage. Single allospecific T cell clones lyse specific or NK-sensitive target cells via distinct recognition structures. Eur. J. Immunol. 14:1984;121.
34. Roberts T.E., Shipton U., Moore M. Role of MHC class I antigens and the CD3 complex in the lysis of autologous human tumors by T cell clones. Int. J. Cancer. 39:1987;436.
35. Rocha B., Vassalli P., Guy-Grand D. The extrathymic T cell development pathway. Immunol. Today. 13:1992;449.
36. Takii Y., Hashimoto S., Iiai T., Watanabe H., Hatakeyama K., Abo T. Increase in the proportion of granulated CD56+ T cells in patients with malignancy. Clin. Exp. Immunol. 97:1994;522.
37. Satoh M., Seki S., Hashimoto W., et al. Cytotoxic γ/δ or α/β T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J. Immunol. 157:1996;3886.
38. Pittet M.J., Speiser D.E., Valmori D., Cerottini J.-C., Romero P. Cytolytic effector function in human circulating CD8+ T cells closely correlated with CD56 surface expression. J. Immunol. 164:2000;1148.
39. Romagnani S. Human TH1 and TH2 subsets regulation of differentiation and role in protection and immunopathology . Intern. Arch. Allergy Immunol. 98:1989;279.
40. Takashi N., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., Ohta A. Distinct role of antigen-specific T helper Type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:1999;617.
41. Ghosh P., Komschlies K.L., Cippitelli M., Longo D.L., Subleski J., Ye J., Sica A., Young H.A., Wiltrout R.H., Ochoa A.C. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87:1995;1478.
42. Clerici M., Shearer G.M., Clerici F. Cytokine dysregulation in invasive carcinoma and other human neoplasias time to consider the TH1/TH2 paradigm . J. Natl. Cancer Inst. 90:1998;261.
43. Karanikas V., Lodding J., Maino V.C., McKenzie I.F. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res. 6:2000;829.
44. Maecker H.T., Auffermann-Gretzinger S., Nomura L.E., Liso A., Czerwinski D.K., Levy R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin. Cancer Res. 7:2001;902s.
45. zum Buschenfelde C.M., Metzger J., Hermann C., Nicklisch N., Peschel C., Bernhard H. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167:2001;1712.